GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » Net Income

China NT Pharma Group Co (HKSE:01011) Net Income : HK$-150.21 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. China NT Pharma Group Co's Net Income for the six months ended in Jun. 2024 was HK$0.71 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-150.21 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. China NT Pharma Group Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.00.


China NT Pharma Group Co Net Income Historical Data

The historical data trend for China NT Pharma Group Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co Net Income Chart

China NT Pharma Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -653.84 -423.91 -183.10 -74.16 -157.06

China NT Pharma Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.10 -42.62 -6.14 -150.92 0.71

China NT Pharma Group Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

China NT Pharma Group Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-36.498+-0.133+-120.424+-0.0010000000000048
=-157.06

China NT Pharma Group Co's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0.845+-0.133+0+0
=0.71

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-150.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China NT Pharma Group Co  (HKSE:01011) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

China NT Pharma Group Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


China NT Pharma Group Co Net Income Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


China NT Pharma Group Co Business Description

Traded in Other Exchanges
N/A
Address
198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Executives
Ieong Chong Mang
Golden Base Investment Limited
Shum Ning
Chin Yu
Ng Tit
Wang Minzhi 2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines